{
    "Clinical Trial ID": "NCT00528567",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Bevacizumab and Chemotherapy",
        "  Participants randomized to receive bevacizumab and chemotherapy",
        "INTERVENTION 2: ",
        "  Chemotherapy",
        "  Participants randomized to receive chemotherapy alone"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  adult patients, >=18 years of age;",
        "  operable primary invasive breast cancer;",
        "  completed definitive loco-regional surgery;",
        "  primary tumor centrally confirmed as triple negative.",
        "Exclusion Criteria:",
        "  locally advanced breast cancers;",
        "  previous breast cancer history;",
        "  clinically significant cardiovascular disease."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Invasive Disease-free Survival (IDFS) Event",
        "  IDFS, was a composite endpoint defined as the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site);Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer or Second primary non-breast invasive cancer.",
        "  Time frame: Event driven (until data cutoff: 29 February 2012: up to 49 months)",
        "Results 1: ",
        "  Arm/Group Title: Bevacizumab and Chemotherapy",
        "  Arm/Group Description: Participants randomized to receive bevacizumab and chemotherapy",
        "  Overall Number of Participants Analyzed: 1301",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  NA  [1]    (NA to NA)",
        "Results 2: ",
        "  Arm/Group Title: Chemotherapy",
        "  Arm/Group Description: Participants randomized to receive chemotherapy alone",
        "  Overall Number of Participants Analyzed: 1290",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  NA  [1]    (NA to NA)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 379/1288 (29.43%)",
        "  Febrile neutropenia  84/1288 (6.52%)",
        "  Neutropenia  69/1288 (5.36%)",
        "  Leukopenia  8/1288 (0.62%)",
        "  Anaemia  1/1288 (0.08%)",
        "  Thrombocytopenia  4/1288 (0.31%)",
        "  Pancytopenia  1/1288 (0.08%)",
        "  Febrile bone marrow aplasia  1/1288 (0.08%)",
        "  Atrial fibrillation  4/1288 (0.31%)",
        "  Cardiac failure congestive  6/1288 (0.47%)",
        "Adverse Events 2:",
        "  Total: 250/1271 (19.67%)",
        "  Febrile neutropenia  59/1271 (4.64%)",
        "  Neutropenia  38/1271 (2.99%)",
        "  Leukopenia  1/1271 (0.08%)",
        "  Anaemia  3/1271 (0.24%)",
        "  Thrombocytopenia  0/1271 (0.00%)",
        "  Pancytopenia  1/1271 (0.08%)",
        "  Febrile bone marrow aplasia  0/1271 (0.00%)",
        "  Atrial fibrillation  2/1271 (0.16%)",
        "  Cardiac failure congestive  0/1271 (0.00%)"
    ]
}